Akari Therapeutics Plc (AKTX) stock forecast and price target
Price $6.80 · data as of November 13, 2026
12-month price target
Average target$25.50
Upside / downside+275.0%
Analysts3
ConsensusNone
Low $19.50Average $25.50High $30.00
Gold marker: average target · white marker: today’s price ($6.80)
Analyst ratings
Strong buy 1Buy 2Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-9.05 | −113025.0% | $0 |
| Next fiscal year ends December 31, 2027 | $-8.65 | +4.4% | $0 |
| Next quarter ends December 31, 2026 | $-2.11 | — | $0 |
| Quarter after ends March 31, 2027 | $-2.09 | +0.0% | $0 |
Consensus of the analysts covering Akari Therapeutics Plc, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the Akari Therapeutics Plc stock price target?
The average 12-month target from 3 analysts is $25.50, 275.0% above the current price of $6.80 Targets range from $19.50 to $30.00.
Is Akari Therapeutics Plc a buy according to analysts?
The consensus rating is “None” (1 strong buy, 2 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Akari Therapeutics Plc expected to earn?
Analysts expect EPS of $-9.05 for the fiscal year ending December 31, 2026 and $-8.65 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.